Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.

Birrell, S N; Roder, D M; Horsfall, D J; Bentel, J M; Tilley, W D

doi:10.1200/jco.1995.13.7.1572

Cited by 88Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.

Birrell, S N, Roder, D M, Horsfall, D J, Bentel, J M, Tilley, W D·1995·Journal of Clinical Oncology

DOI 10.1200/jco.1995.13.7.1572

Open this paper in CoChat — free account

Abstract

PURPOSE: To determine the predictive value of androgen receptor (AR) levels in primary tumors of women who undergo medroxyprogesterone acetate (MPA) therapy for advanced breast cancer after relapse on tamoxifen adjuvant therapy. METHODS: Between 1984 and 1987 at Flinders Medical Centre, South Australia, 136 postmenopausal women received adjuvant tamoxifen therapy for lymph node-positive breast cancer. Estrogen receptor (ER), progesterone receptor (PgR), and AR levels, tumor size, and degree of axillary node involvement were determined at the time of diagnosis. The median follow-up period was 81 months; 89 women developed metastatic disease, 83 of whom subsequently received MPA (500 mg/d). The objective response rate ([RR] ie, complete response [CR] and partial response [PR]) and progression-free interval (PFI) were assessed in response to MPA therapy. Associations between RR, PFI, and primary tumor characteristics including ER, PgR, and AR levels were examined using the Mann-Whitney U test, Kaplan-Meier product-limit estimator, and Cox proportional hazards regression, as appropriate. RESULTS: Thirty-two of 83 patients (38.6%) responded to MPA. RR was significantly associated with the presence of AR (P < .001), but not with other primary tumor characteristics or duration of tamoxifen therapy. After initiation of MPA treatment, PFI increased with increasing concentration of AR in the primary tumor. CONCLUSION: Response to MPA after adjuvant tamoxifen treatment for lymph node-positive breast cancer was positively associated with AR level in the primary tumor. This finding suggests that MPA action in breast cancer may be mediated in part by the AR.

Integrity signals

Registry

Crossref · 10.1200/jco.1995.13.7.1572

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

AR plays a role in the beneficial effects of MPA in breast cancer in women.
“thus suggesting the role of AR in the beneficial effects of MPA in breast cancer in women (246, 247).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [247]

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 315,771 · see citing works
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,442 · see citing works
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,191 · see citing works
Endocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399 · see citing works
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
Encarnaci�n, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., & Osborne, C. K. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665801 · Cited by 194 · see citing works
Improved measurement of androgen receptors in human breast cancer.
Lea, O. A., Kvinnsland, S., & Thorsen, T. (1989) · PubMed · Cited by 138 · see citing works
Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.
Teulings, F. A. G., van Gilse, H. A., Henkelman, M. S., Portengen, H., & Alexieva-Figusch, J. (1980) · PubMed · Cited by 103 · see citing works
MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression
Hall, R. E., Birrell, S. N., Tilley, W. D., & Sutherland, R. L. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90424-3 · Cited by 100 · see citing works
Self-citation
Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Poulin, R., Baker, D., Poirier, D., & Labrie, F. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01806528 · Cited by 83 · see citing works
Androgen sensitivity of the new human breast cancer cell line MFM-223.
Hackenberg, R., Lüttchens, S., Hofmann, J., Kunzmann, R., Hölzel, F., & Schulz, K.-D. (1991) · PubMed · Cited by 76 · see citing works
Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor
Hackenberg, R., Hawighorst, T., Filmer, A., Nia, A. H., & Schulz, K.-D. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00689836 · Cited by 57 · see citing works
An overview of megestrol acetate for the treatment of advanced breast cancer.
SEDLACEK, S. M. (1988) · PubMed · Cited by 55 · see citing works
Untitled work
(1992) · PubMed · Cited by 50 · see citing works
Androgens and breast cancer.
Labrie, F., Simard, J., de Launoit, Y., Poulin, R., Thériault, C., Dumont, M., Dauvois, S., Martel, C., & Li, S. M. (1992) · PubMed · Cited by 45 · see citing works
Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary carcinoma cell growth
Hackenberg, R., Hofmann, J., Wolff, G., Hölzel, F., & Schulz, K. D. (1990) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01613000 · Cited by 26 · see citing works
Untitled work
Bryan (1984) · doi:10.1002/1097-0142(19841201)54:11

Flagged first, then by citations

Sorted by citations

Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · see citing works
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco‐Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Li, J., Moore, N. L. T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 406 · see citing works
Self-citation
Breast and prostate cancer: more similar than different
Risbridger, G. P., Davis, I. D., Birrell, S. N., & Tilley, W. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2795 · Cited by 248 · see citing works
Self-citation
Androgens induce divergent proliferative responses in human breast cancer cell lines
Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., & Tilley, W. D. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00005-k · Cited by 245 · see citing works
Self-citation
Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer
Kono, M., Fujii, T., Lim, B., Karuturi, M. S., Tripathy, D., & Ueno, N. T. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4975 · Cited by 214 · see citing works
Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women
Somboonporn, W., & Davis, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0016 · Cited by 214 · see citing works
Distinguishing Androgen Receptor Agonists and Antagonists: Distinct Mechanisms of Activation by Medroxyprogesterone Acetate and Dihydrotestosterone
Kemppainen, J., Langley, E., Wong, C.-I., Bobseine, K., KELCE, W. R., & Wilson, E. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.3.0255 · Cited by 207 · see citing works
Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers
Ogawa, Y., Hai, E., Matsumoto, K., Ikeda, K., Tokunaga, S., Nagahara, H., Sakurai, K., Inoue, T., & Nishiguchi, Y. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0770-6 · Cited by 183 · see citing works
Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells
Yeap, B. B., Krueger, R. G., & Leedman, P. J. (1999) · Endocrinology · doi:10.1210/endo.140.7.6769 · Cited by 149 · see citing works
Novel Binding of HuR and Poly(C)-binding Protein to a Conserved UC-rich Motif within the 3′-Untranslated Region of the Androgen Receptor Messenger RNA
Yeap, B. B., Voon, D. C., Vivian, J. P., McCulloch, R. K., Thomson, A. M., Giles, K. M., Czyzyk-Krzeska, M., Furneaux, H., Wilce, M. C. J., Wilce, J. A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202883200 · Cited by 141 · see citing works
Androgen Replacement in Women: A Commentary
Davis, S. R. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5802 · Cited by 133 · see citing works
Deciphering the divergent roles of progestogens in breast cancer
Carroll, J. S., Hickey, T. E., Tarulli, G. A., Williams, M. R., & Tilley, W. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.116 · Cited by 126 · see citing works
Self-citation
Role of the androgen receptor in human breast cancer.
Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018730519839 · Cited by 124 · see citing works
Self-citation
Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., & Tilley, W. D. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00109-4 · Cited by 110 · see citing works
Self-citation
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis
Aleskandarany, M. A., Abduljabbar, R. F., Ashankyty, I., Elmouna, A., Jerjees, D. A., Ali, S., Buluwela, L., Diez, M., Caldas, C., Green, A. R., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3934-5 · Cited by 101 · see citing works
Extramammary Paget Disease Is Characterized by the Consistent Lack of Estrogen and Progesterone Receptors But Frequently Expresses Androgen Receptor
de Leon, E. D., Carcangiu, M. L., Prieto, V. G., McCue, P. A., Burchette, J. L., To, G. T., Norris, B. A., Kovatich, A. J., Sánchez, R. L., Krigman, H. R., et al. (2000) · American Journal of Clinical Pathology · doi:10.1309/p756-xxcb-tv71-u4xv · Cited by 102 · see citing works
EJE PRIZE 2016: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer
Carroll, J. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0124 · Cited by 91 · see citing works
Androgen receptor as a targeted therapy for breast cancer.
Garay, J. P., & Park, B. H. (2012) · Europe PMC (PubMed Central) · Cited by 90 · see citing works
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer
Birrell, S. N., Butler, L. M., Harris, J. M., Buchanan, G., & Tilley, W. D. (2007) · The FASEB Journal · doi:10.1096/fj.06-7518com · Cited by 90 · see citing works
Self-citation
Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene
Bièche, I. (2001) · Carcinogenesis · doi:10.1093/carcin/22.9.1521 · Cited by 87 · see citing works
Expression of GCDFP‐15 and AR decreases in larger or node‐positive apocrine carcinomas of the breast
Honma, N., Takubo, K., Akiyama, F., Sawabe, M., Arai, T., Younes, M., Kasumi, F., & Sakamoto, G. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02181.x · Cited by 74 · see citing works
Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats
Chaux, P., Favre, N., Martin, M., & Martin, F. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970807)72:4 · Cited by 185 · see citing works
Expression of androgen receptor and prostate-specific antigen in male breast carcinoma
Kidwai, N., Gong, Y. Y., Sun, X., Deshpande, C. G., Yeldandi, A. V., Rao, M. S., & Badve, S. (2003) · Breast Cancer Research · doi:10.1186/bcr733 · Cited by 72 · see citing works
Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer
Hall, R., Aspinall, J., Horsfall, D., Birrell, S., Bentel, J. M., Sutherland, R. L., & Tilley, W. D. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.513 · Cited by 71 · see citing works
Self-citation
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer
Narayanan, R., & Dalton, J. T. (2016) · Cancers · doi:10.3390/cancers8120108 · Cited by 68 · see citing works
Androgen receptor expression in male breast carcinoma: lack of clinicopathological association
Pich, A., Margaria, E., Chiusa, L., Candelaresi, G., & Canton, O. D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690153 · Cited by 68 · see citing works
Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate
Buchanan, G., Birrell, S. N., Peters, A. A., Bianco‐Miotto, T., Ramsay, K., Cops, E. J., Yang, M., Harris, J. M., Simila, H. A., Moore, N. L. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3077 · Cited by 68 · see citing works
Self-citation
The role of androgen receptor in breast cancer
Iacopetta, D., Rechoum, Y., & Fuqua, S. A. W. (2012) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2012.11.003 · Cited by 67 · see citing works
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells
Ghatge, R. P., Jacobsen, B. M., Schittone, S. A., & Horwitz, K. B. (2005) · Breast Cancer Research · doi:10.1186/bcr1340 · Cited by 65 · see citing works
The androgen receptor mRNA
Yeap, B. B., Wilce, M. C. J., & Leedman, P. J. (2004) · BioEssays · doi:10.1002/bies.20051 · Cited by 63 · see citing works
Hormonal therapy of breast cancer
Locker, G. Y. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90051-2 · Cited by 63 · see citing works
The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.
Jiao, Q., Wu, A., Shao, G.-L., Peng, H., Wang, M., Ji, S., Liu, P., & Zhang, J. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.08.13 · Cited by 57 · see citing works
Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial
Bines, J., Dienstmann, R., Obadia, R., Branco, L. G., Quintella, D. C., Castro, T., Camacho, P., Soares, F. A., & Costa, M. E. F. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu015 · Cited by 56 · see citing works
Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status
Honma, N., Sakamoto, G., Akiyama, F., Esaki, Y., Sawabe, M., Arai, T., Hosoi, T., Harada, N., Younes, M., & Takubo, K. (2003) · Histopathology · doi:10.1046/j.1365-2559.2003.01542.x · Cited by 54 · see citing works
Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours
Hall, R. E., Clements, J. A., Birrell, S. N., & Tilley, W. D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.499 · Cited by 53 · see citing works
Self-citation
Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells
Moore, N. L. T., Hickey, T. E., Butler, L. M., & Tilley, W. D. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.019 · Cited by 46 · see citing works
Self-citation
Androgen receptor status in female breast cancer: RT-PCR and Western blot studies
Bryś, M., Wójcik, M., Romanowicz‐Makowska, H., & Krajewska, W. M. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320100294 · Cited by 46 · see citing works
Non-canonical AR activity facilitates endocrine resistance in breast cancer
Chia, K., Milioli, H. H., Portman, N., Laven‐Law, G., Coulson, R. S., Yong, A., Segara, D., Parker, A., Caldon, C. E., Deng, N., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0333 · Cited by 42 · see citing works
Self-citation
Androgen Receptor Expression Along with Loss of bcl-2, ER, and PR Expression in Benign and Malignant Apocrine Lesions of the Breast: Implications for Therapy
Tavassoli, F. A., Purcell, C. A., Bratthauer, G. L., & Man, Y. (1996) · The Breast Journal · doi:10.1111/j.1524-4741.1996.tb00107.x · Cited by 40 · see citing works
Postmenopausal testosterone therapy and breast cancer risk
Somboonporn, W., & Davis, S. R. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.06.020 · Cited by 40 · see citing works
Pushing estrogen receptor around in breast cancer
Lim, E., Tarulli, G. A., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0427 · Cited by 39 · see citing works
Self-citation
Dehydroepiandrosterone, androgens and the mammary gland
Labrie, F. (2006) · Gynecological Endocrinology · doi:10.1080/09513590600624440 · Cited by 39 · see citing works
Androgen treatment in women
Davis, S. R. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127881.x · Cited by 36 · see citing works
Non-genomic effects of progestins—inhibition of cell growth and increased intracellular levels of cyclic nucleotides
Sager, G., Ørbo, A., Jæger, R., & Engström, C. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00269-8 · Cited by 33 · see citing works
An Analysis of Serum Interleukin-6 Levels to Predict Benefits of Medroxyprogesterone Acetate in Advanced or Recurrent Breast Cancer
Nishimura, R., 長尾, 和., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Yamashita, H., Fukuda, M., Mizumoto, T., & Hamamoto, R. (2000) · Oncology · doi:10.1159/000012155 · Cited by 33 · see citing works
Medroxyprogesterone Acetate Decreases Secretion of Interleukin-6 and Parathyroid Hormone-Related Protein in a New Anaplastic Thyroid Cancer Cell Line, KTC-2
Kurebayashi, J., Otsuki, T., Tanaka, K., Yamamoto, Y., Moriya, T., & Sonoo, H. (2003) · Thyroid · doi:10.1089/105072503321582042 · Cited by 30 · see citing works
Expression of Structurally Unaltered Androgen Receptor in Extramammary Paget's Disease
Fujimoto, A., Takata, M., Hatta, N., & Takehara, K. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780153 · Cited by 30 · see citing works
Cancer in Australia 2000
Stevenson, C., Leeds, K., & McDermid, I. (2003) · Deakin Research Online (Deakin University) · Cited by 30 · see citing works
Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy
Honma, N., Horii, R., Iwase, T., Saji, S., Younes, M., Ito, Y., & Akiyama, F. (2012) · Breast Cancer · doi:10.1007/s12282-012-0337-2 · Cited by 29 · see citing works
Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?
Stanczyk, F. Z., & Bhavnani, B. R. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.11.011 · Cited by 29 · see citing works
Androgen Resistance in Female Mice Increases Susceptibility to DMBA-Induced Mammary Tumors
Simanainen, U., Gao, Y., Walters, K. A., Watson, G., Desai, R., Jimenez, M., & Handelsman, D. J. (2012) · Hormones and Cancer · doi:10.1007/s12672-012-0107-9 · Cited by 27 · see citing works
Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne, M., Gebski, V., Forbes, J., Tattersall, M. H. N., Simes, R. J., Coates, A. S., Dewar, J. M., Lunn, M., Flower, C., Gill, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3141 · Cited by 26 · see citing works
Prognostic relevance of androgen receptor detection in operable breast cancer
Søiland, H., Kørner, H., Skaland, I., Janssen, E. A. M., Gudlaugsson, E. G., Varhaug, J. E., Baak, J. P. A., & Søreide, J. A. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21156 · Cited by 25 · see citing works
Hormone therapy and breast cancer: emerging steroid receptor mechanisms
Perkins, M., Toit, R. L.-D., & Africander, D. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0094 · Cited by 25 · see citing works
Male breast cancer
Reis, L. O., Dias, F. G. F., Castro, M. A., & Ferreira, U. (2011) · The Aging Male · doi:10.3109/13685538.2010.535048 · Cited by 24 · see citing works
Endocrine therapy of breast cancer
Goldhirsch, A., Colleoni, M. A., & Gelber, R. D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf640 · Cited by 24 · see citing works
Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression
Tanaka, Y., Kato, K., Mibu, R., Uchida, S., Asanoma, K., Hashimoto, K., Nozaki, M., & Wake, N. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318156fb77 · Cited by 24 · see citing works
Role of corticotropin-releasing hormone family peptides in androgen receptor and vitamin D receptor expression and translocation in human breast cancer MCF-7 cells
Jin, L., Chen, C. Y., Guo, R., Wan, R., & Li, S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.03.034 · Cited by 20 · see citing works
Cancer in Australia 1998
Stevenson, C., Harding, J., Caldwell, I. P., O'Brien, K. E., Leeds, K., Brockway, I., Dunn, C., Markey, J., van der Hoek, R., Grayson, N., et al. (2001) · Deakin Research Online (Deakin University) · Cited by 18 · see citing works
Expression of oestrogen receptor‐β in apocrine carcinomas of the breast
Honma, N., Takubo, K., Akiyama, F., Kasumi, F., Sawabe, M., Arai, T., Hosoi, T., Yoshimura, N., Harada, N., Younes, M., et al. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02636.x · Cited by 17 · see citing works
Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor
Moore, N. L. T., Hanson, A. R., Ebrahimie, E., Hickey, T. E., & Tilley, W. D. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105548 · Cited by 17 · see citing works
Self-citation
Transgenic introduction of androgen receptor into estrogen-receptor–, progesterone-receptor–, and androgen-receptor–negative breast cancer cells renders them responsive to hormonal manipulation
Garreau, J. R., Muller, P., Pommier, R. F., & Pommier, S. J. (2006) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.02.004 · Cited by 16 · see citing works
Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b
Snell, C. E., Gough, M., Liu, C., Middleton, K., Pyke, C., Shannon, C., Woodward, N. E., Hickey, T. E., Armes, J. E., & Tilley, W. D. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0331-3 · Cited by 13 · see citing works
Self-citation
Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer
Nishimura, R., Nagao, K., Matsuda, M., Baba, K., Matsuoka, Y., Yamashita, H., Fukuda, M., Higuchi, A., & Ikeda, K. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00125-1 · Cited by 13 · see citing works
Endocrine Treatment of Advanced Breast Cancer
Dowsett, M. (1996) · Acta Oncologica · doi:10.3109/02841869609083973 · Cited by 13 · see citing works
The cellular and molecular effects of the androgen receptor agonist, Cl-4AS-1, on breast cancer cells
Ahram, M. A., Mustafa, E. H., Hammad, S. A., Alhudhud, M., Bawadi, R., Tahtamouni, L. H., Khatib, F. A., & Zihlif, M. (2018) · Endocrine Research · doi:10.1080/07435800.2018.1455105 · Cited by 11 · see citing works
Collaborative work on evaluation of ovarian toxicity 1) Effects of 2- or 4-week repeated-dose administration and fertility studies with medroxyprogesterone acetate in female rats
Ohtake, S., Fukui, M., & Hisada, S. (2009) · The Journal of Toxicological Sciences · doi:10.2131/jts.34.s23 · Cited by 11 · see citing works
Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women
Singh, L. C., Chakraborty, A., Mishra, A. K., Devi, T. R., Sugandhi, N., Chintamani, C., Bhatnagar, D., Kapur, S., & Saxena, S. (2011) · Medical Oncology · doi:10.1007/s12032-011-9952-6 · Cited by 10 · see citing works
Suppression of parathyroid hormone‐related protein messenger RNA expression by medroxyprogesterone acetate in breast cancer tissues
Sugimoto, T., Shiba, E., Watanabe, T., & Takai, S. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006254006088 · Cited by 10 · see citing works
Antiprogestins for breast cancer treatment: We are almost ready
Elia, A. M., Pataccini, G., Saldain, L., Ambrosio, L., Lanari, C., & Rojas, P. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106515 · Cited by 8 · see citing works
Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?”
Stanczyk, F. Z., & Bhavnani, B. R. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.08.013 · Cited by 8 · see citing works
Expression of 5α‐reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness
Kasashima, S., Kawashima, A., Ozaki, S., & Nakanuma, Y. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04214.x · Cited by 7 · see citing works
The Activity of Medroxyprogesterone Acetate, an Androgenic Ligand, in Ovarian Cancer Cell Invasion
Gogoi, R. P., Kudla, M. J., Gil, O. D., & Fishman, D. A. (2008) · Reproductive Sciences · doi:10.1177/1933719108323446 · Cited by 7 · see citing works
Homologous ELISA for measurement of medroxyprogesterone acetate in serum
Dutta, P., Shrivastav, T. G., & Thakur, S. C. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.07.010 · Cited by 5 · see citing works
Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer
Meng, X.-Y., Wu, S., Jiang, Z., Sun, B., Ma, Y., Zhao, X., Ding, L., Wang, Y., Wang, T., Zhang, S., et al. (2013) · Swiss Medical Weekly · doi:10.4414/smw.2013.13765 · Cited by 4 · see citing works
Quantitative Analysis of Adrenal Cortical Histological Alterations After Application of Medroxyprogesterone Acetate
Mitevska, E., & Spiroski, M. Z. (2010) · Macedonian Journal of Medical Sciences · doi:10.3889/mjms.1857-5773.2010.0122 · Cited by 3 · see citing works
Rationale for Treating Hypoandrogenism in Women
Davis, S. R. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-388-0_19 · Cited by 2 · see citing works
Mechanisms of Resistance to Antiestrogens and Their Implications for Crossresistance
Clarke, R. C., & Lippman, M. E. (1996) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4092-1_5 · Cited by 2 · see citing works
Side effects of androgen treatment
Bükülmez, O., & Carr, B. R. (2005) · CRC Press eBooks · doi:10.1201/b14632-14 · Cited by 2 · see citing works
Proteomics analysis reveals progesterone receptor induced mitochondria-mediated apoptosis in breast cancer cells
Woo, Q. Y., Lau, P. K., Lee, B. T. K., Bajalović, N., Lee, S. H., Leong, K. S., Pow, K. Y., Hanan, S., Meng, W., Lai, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-28183-3 · Cited by 1 · see citing works
Androgens and the androgen receptor (AR)
Moore, N. L. T., Centenera, M. M., Butler, L. M., Hickey, T. E., & Tilley, W. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.033 · Cited by 1 · see citing works
Self-citation
Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq
Eduardo, M. B., Keller, I., Schuster, N., Aebi, S. P., & Jaggi, R. B. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00541-6 · Cited by 1 · see citing works
Androgens
Davis, S. R. (2000) · Elsevier eBooks · doi:10.1016/b978-012453790-3/50032-9 · Cited by 1 · see citing works
COMMENTARY Androgen Replacement in Women: A Commentary
Davis, S. R. (1999)
Intervention: Androgens
Davis, S. R. (2007) · Elsevier eBooks · doi:10.1016/b978-012369443-0/50068-5
Additional file 2 of Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq
Eduardo, M. B., Keller, I., Schuster, N., Aebi, S. P., & Jaggi, R. B. (2023) · Figshare · doi:10.6084/m9.figshare.23902893
Omics analysis reveals striking effects of progesterone receptor on mitochondria and mitochondria-mediated apoptosis independent of caspases in Breast Cancer cellsPreprint
Woo, Q. Y., Lau, P. K., Kwong, B. L. T., Bajalović, N., Lee, S. H., Leong, K. S., Pow, K. Y., Hanan, S., Meng, W., Lai, S. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.06.641096
Additional file 1 of Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq
Bustamante Eduardo, M., Keller, I., Schuster, N., Aebi, S., & Jaggi, R. B. (2023) · Figshare · doi:10.6084/m9.figshare.23902890

Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate
Buchanan, G., Birrell, S. N., Peters, A. A., Bianco‐Miotto, T., Ramsay, K., Cops, E. J., Yang, M., Harris, J. M., Simila, H. A., Moore, N. L. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3077 · Cited by 68 · see citing works
Self-citation
Role of the androgen receptor in human breast cancer.
Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018730519839 · Cited by 124 · see citing works
Self-citation
Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura, Y., Tashiro, H., Hisamatsu, K., & Shinozuka, K. (1988) · PubMed · Cited by 2 · see citing works
Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., & Tilley, W. D. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00109-4 · Cited by 110 · see citing works
Self-citation
Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?
Rocca, A., Bronte, G., Ravaioli, S., Puccetti, M., Tumedei, M. M., Scarpi, E., Maltoni, R., Sarti, S., Cecconetto, L., Bedei, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1042 · Cited by 1 · see citing works

Authors: Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D.
Affiliations: Flinders University (AU)
ORCID: Birrell, S N
Roder, D M
Bentel, J M
Tilley, W D
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1995-07
Volume: 13
Issue: 7
Pages: 1572-1577
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1995.13.7.1572
OpenAlex: W2180179507
Cited by: 87
References: 16
Citations by year: 2025: 2 · 2024: 1 · 2023: 2 · 2019: 1 · 2018: 5 · 2017: 1 · 2016: 5 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 6
FWCI: 1.81
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders: Royal Australasian College of Surgeons
Flinders University
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
Keywords: medroxyprogesterone acetate, advanced breast cancer, androgen receptor expression, tamoxifen resistance, node-positive breast cancer, metastatic breast cancer, predictive biomarkers, progesterone receptor, estrogen receptor, progression-free interval, postmenopausal women
MeSH terms: Adult, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Prospective Studies, Receptors, Androgen, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Chemotherapy, Adjuvant, Treatment Failure, Medroxyprogesterone Acetate, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks